- Global Pharma News & Resources

Centrillion Technologies Announces WeDoctor Partnership

PALO ALTO, Calif., July 31, 2018 /PRNewswire/ -- Centrillion Technologies, an innovator in building transformative genomic analysis tools announced that it has entered into a partnership with WeDoctor Holdings Limited ("WeDoctor"), China's leading technology-enabled medical and healthcare solutions platform. The strategic cooperation agreement includes a multi-million US dollar investment by WeDoctor and establishes with Centrillion (Hangzhou) Co., Ltd. a joint venture to provide the most advanced DNA chips and genomic analysis services.

"This partnership leverages the complementary strengths of our organizations," stated Wei Zhou, Founder and CEO, Centrillion.  "We are committed to providing third-generation DNA chips for multi-dimensional in situ biomolecule sequencing analysis, detecting DNA, RNA, and protein in two-dimensional or three-dimensional tissue sections. This powerful technology can be used to analyze tumor biopsies and maintain intercellular information exchange."

Jerry Liao, Chairman and Chief Executive Officer of WeDoctor, said, "In the past eight years, WeDoctor has continued to secure the medical supply system and formed the core competence of 'Cloud + HMO'. The WeDoctor platform has gathered 110 million users. Gene detection technologies play an important role in serving users for screening and health management. The leading technological advantage of Centrillion will greatly enhance the service capacity of the WeDoctor HMO system. We are very proud to partner with Centrillion to accelerate progress through investment and cooperation."

The growth potential of China's market for genomic analysis tools is substantial. With this partnership Centrillion will provide resource support for advanced portable gene tester prototypes, high-throughput wafers, related technologies, and management teams to create with WeDoctor, products with core competitiveness. At the same time, WeDoctor will fully provide and share its medical platform resources with Centrillion. As of December 2017, WeDoctor's online platform had more than 220,000 doctors and more than 110 million registered users. WeDoctor will employ its enormous user base and physician resources to accelerate the utilization of genomic products in China.

About WeDoctor

We Doctor Holdings Limited ("WeDoctor") is China's leading technology-enabled healthcare solutions platform, providing seamless online and offline healthcare services as well as integration of general practitioner and specialist doctors.  On the WeDoctor platform, there are over 2,700 hospitals, 220,000 leading doctors, 15,000 pharmacies and 27 million monthly active users. Since the establishment of China's largest appointment registration platform --, WeDoctor has continued to transform the healthcare system through technology with the creation of the nation's first Internet hospital - Wuzhen Internet Hospital. It also launched the industry's first domestic smart health terminal, and has made significant progress in the field of smart healthcare with the creation of AI-enabled diagnosis systems for both Western and Chinese medicine.

About Centrillion

Centrillion Technologies is a genomics sensor technology provider implementing advanced biochemistry, engineering, and manufacturing to advance the use of genomics.

Centrillion's Molecular Vision Laboratory (MVL) the only molecular diagnostic laboratory in the United States specializing in eye diseases, is a leader in identification of genetic mutations in vision disorders and is establishing the world's leading genetic database for eye diseases.

Editor Details

Last Updated: 31-Jul-2018